Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Savara Pharmaceuticals

Request full access

An inhaled antibiotic for mrsa infection in cystic fibrosis

Austin, United StatesFounded 2007Biotech & Life Sciences

About Savara Pharmaceuticals

Savara Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare respiratory diseases. The company primarily serves patients with unmet medical needs, particularly those suffering from conditions such as autoimmune pulmonary alveolar proteinosis (aPAP) and non-cystic fibrosis bronchiectasis (NCFB). Operating in the orphan lung disease market, Savara's business model revolves around conducting advanced clinical trials to bring novel treatments to market.

Savara's revenue model is based on the successful development and commercialization of its drug candidates. The company is currently engaged in multiple clinical studies, including a pivotal Phase 3 study called AVAIL, which evaluates AeroVanc for treating MRSA in cystic fibrosis patients. Another key project is the Phase 3 clinical study of Molgradex for aPAP, with plans to discuss a confirmatory study for NCFB with the U.S. Food and Drug Administration (FDA).

By focusing on rare diseases, Savara aims to provide better treatment options for patients who have limited alternatives. The company's strategic approach includes leveraging its expertise in respiratory conditions to develop targeted therapies that can significantly improve patient outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2007
Headquarters
Austin, United States
Listing
IPO 2017
Employees
126
Open positions
19
Dealroom signal
88.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Risk Management, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Jun 2016
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Jan 2026 $0 — Hercules Capital ↗
POST IPO EQUITY✓Other financing Oct 2025 $130M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $2M — −$122M -6061.4% −$119M -5883% $81M
2025 $0 — −$122M — −$119M — $81M
2024 $0 — −$102M — −$96M — $78M
2023 $0 — −$59M — — $44M
2022 $0 -100% −$38M — —
2021 $257K 0% −$40M -15667.7%
2020 $257K — −$48M -18565.8%
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Savara Pharmaceuticals website traffic

Latest recorded traffic for Savara Pharmaceuticals is 5.6K monthly website visits, up 24.4% over the last three months. Savara Pharmaceuticals's team grew 250% over the past year.

Latest monthly visits5.6K 3-month web change+24.4% 1-year team growth+250%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Savara Pharmaceuticals in the Austin ecosystem

Live from Dealroom

The Savara Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

31 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cystic Fibrosis Foundation

Series A6 investors entered at this stage

  • Keiretsu Forum Mid Atlantic
  • Green Park & Golf Ventures
  • Keiretsu Forum Northwest
  • Keiretsu Forum
  • Rady Venture Fund
  • Tech Coast Angels

Series B and later14 investors entered at this stage

  • Haas Portman
  • Keiretsu Capital
  • Carthona Capital
  • Standard Treasury
  • Silicon Valley Bank
  • Wellington Management
  • TCGX
  • Bain Capital Life Sciences
  • Farallon Capital Management
  • Nantahala Capital Management
  • First Light Asset Management
  • Frazier Life Sciences
  • Hercules Capital
  • RTW Investments

Other known investors10 additional known investors

  • Mast Therapeutics
  • University of Kansas
  • 37 Ventures
  • Austin Technology Incubator
  • Central Texas Angel Network
  • James Synge
  • Keiretsu Forum Australiasia
  • Puget Sound Venture Club
  • Small Business Innovation Research
  • Wild Basin Investments
Team profiled 29 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States91.4%
🇦🇷 Argentina4.3%
🇪🇸 Spain2.1%
🇩🇰 Denmark2.1%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Savara Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Savara Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.